{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:01Z","timestamp":1787063101623,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.073","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T10:35:53Z","timestamp":1573468553000},"page":"942-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes"],"prefix":"10.1016","volume":"38","author":[{"given":"Jasmin","family":"Federizon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Marcinkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-5350","authenticated-orcid":false,"given":"Iain L.","family":"Mainprize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie K.B.","family":"Wills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Pin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-884X","authenticated-orcid":false,"given":"Jonathan F.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.073_b0005","first-page":"496","article-title":"Borrelia burgdorferi sp. nov.: etiologic agent of lyme disease","volume":"34","author":"Johnson","year":"1984","journal-title":"Int J Syst Evol Microbiol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM198303313081301","article-title":"The spirochetal etiology of lyme disease","volume":"308","author":"Steere","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.10.073_b0015","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","article-title":"Lyme borreliosis","volume":"2","author":"Steere","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2019.10.073_b0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2018\/5719081","article-title":"\u201cTicking Bomb\u201d: the impact of climate change on the incidence of lyme disease","volume":"2018","author":"Dumic","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0025","series-title":"Climate change and adaptation strategies for human health","first-page":"157","article-title":"Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures","author":"Lindgren","year":"2006"},{"key":"10.1016\/j.vaccine.2019.10.073_b0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2004.10.027","article-title":"TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi","volume":"119","author":"Pal","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.10.073_b0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.183.1.271","article-title":"Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine","volume":"183","author":"de Silva","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.10.073_b0040","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1073\/pnas.89.12.5418","article-title":"Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice","volume":"89","author":"Fikrig","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.10.073_b0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/IAI.67.1.30-35.1999","article-title":"Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks","volume":"67","author":"de Silva","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.073_b0050","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1006\/jmbi.2000.4119","article-title":"Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA","volume":"302","author":"Ding","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/jmbi.1998.1930","article-title":"NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies","volume":"281","author":"Huang","year":"1998","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/cdli.1.4.406-412.1994","article-title":"Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains","volume":"1","author":"Jiang","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jmb.2005.04.066","article-title":"Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA","volume":"350","author":"Koide","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0070","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acs.bioconjchem.9b00167","article-title":"Antigen engineering approaches for lyme disease vaccines","volume":"30","author":"Federizon","year":"2019","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.vaccine.2019.10.073_b0075","first-page":"96","article-title":"Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi","volume":"1","author":"Conlon","year":"2000","journal-title":"Vet Ther"},{"key":"10.1016\/j.vaccine.2019.10.073_b0080","first-page":"420","article-title":"Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection","volume":"3","author":"Levy","year":"2002","journal-title":"Vet Ther"},{"key":"10.1016\/j.vaccine.2019.10.073_b0085","first-page":"123","article-title":"Confirmation of presence of Borrelia burgdorferi outer surface protein C antigen and production of antibodies to Borrelia burgdorferi outer surface protein C in dogs vaccinated with a whole-cell Borrelia burgdorferi Bacterin","volume":"8","author":"Levy","year":"2010","journal-title":"Intern J Appl Res Vet Med"},{"key":"10.1016\/j.vaccine.2019.10.073_b0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2460\/javma.1992.201.03.403","article-title":"Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin","volume":"201","author":"Chu","year":"1992","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2019.10.073_b0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00373-08","article-title":"Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease","volume":"16","author":"LaFleur","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0100","article-title":"Vanguard\u00ae crLyme: chimeric recombinant vaccine technology for broad-spectrum protection against canine","author":"Ball","year":"2015","journal-title":"Lyme Disease"},{"key":"10.1016\/j.vaccine.2019.10.073_b0105","doi-asserted-by":"crossref","first-page":"e113294","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.073_b0110","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1016\/j.vaccine.2015.07.095","article-title":"Characterization and optimization of a novel vaccine for protection against Lyme borreliosis","volume":"33","author":"Comstedt","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.073_b0115","doi-asserted-by":"crossref","first-page":"e0184357","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.10.073_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2019.10.073_b0125","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.vaccine.2017.04.079","article-title":"Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: implications for vaccine development","volume":"35","author":"Izac","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.073_b0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/1046-5928(90)90011-M","article-title":"Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA","volume":"1","author":"Dunn","year":"1990","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2019.10.073_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/iai.61.1.81-90.1993","article-title":"Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA","volume":"61","author":"Erdile","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.073_b0140","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1128\/iai.62.10.4632-4636.1994","article-title":"Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification","volume":"62","author":"Weis","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.073_b0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine Adjuvants: from 1920 to 2015 and Beyond","volume":"3","author":"Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2019.10.073_b0150","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","article-title":"Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens","volume":"364","author":"Perrie","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2019.10.073_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(91)90120-5","article-title":"Liposomes as carriers of antigens and adjuvants","volume":"140","author":"Alving","year":"1991","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2019.10.073_b0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/cimm.2000.1640","article-title":"Lipoproteins from Borrelia burgdorferi applied in liposomes and presented by dendritic cells induce CD8+ T-lymphocytes in vitro","volume":"201","author":"Beermann","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0170","doi-asserted-by":"crossref","unstructured":"Tur\u00e1nek J, Ma\u0161ek J, K\u0159upka M, Ra\u0161ka M. Functionalised nanoliposomes for construction of recombinant vaccines: lyme disease as an example. In: Giese M, editor. Molecular vaccines: from prophylaxis to therapy - volume 2. Cham: Springer International Publishing; 2014. p. 561\u201377.","DOI":"10.1007\/978-3-319-00978-0_10"},{"key":"10.1016\/j.vaccine.2019.10.073_b0175","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nchem.2236","article-title":"Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens","volume":"7","author":"Shao","year":"2015","journal-title":"Nat Chem"},{"key":"10.1016\/j.vaccine.2019.10.073_b0180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jconrel.2012.02.017","article-title":"Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP","volume":"160","author":"Krupka","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2019.10.073_b0185","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41565-018-0271-3","article-title":"A malaria vaccine adjuvant based on recombinant antigen binding to liposomes","volume":"13","author":"Huang","year":"2018","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0190","doi-asserted-by":"crossref","first-page":"1800011","DOI":"10.1002\/adbi.201800011","article-title":"Adjuvant and antigen systems for malaria transmission-blocking vaccines","volume":"2","author":"Huang","year":"2018","journal-title":"Adv Biosyst"},{"key":"10.1016\/j.vaccine.2019.10.073_b0195","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/IAI.70.4.2139-2150.2002","article-title":"Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background","volume":"70","author":"Elias","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.10.073_b0200","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1603\/ME13180","article-title":"A silicone membrane for in vitro feeding of Ixodes scapularis (Ixodida: Ixodidae)","volume":"51","author":"Andrade","year":"2014","journal-title":"J Med Entomol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ps.1293","article-title":"An in vitro feeding assay to test acaricides for control of hard ticks","volume":"63","author":"Krober","year":"2007","journal-title":"Pest Manag Sci"},{"key":"10.1016\/j.vaccine.2019.10.073_b0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/jme\/tjv157","article-title":"Infection rate by trypanosoma cruzi and biased vertebrate host selection in the Triatoma dimidiata (Hemiptera: Reduvidae) species complex","volume":"53","author":"Ramirez-Sierra","year":"2016","journal-title":"J Med Entomol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0215","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ttbdis.2018.03.033","article-title":"Identification of Lyme borreliae proteins promoting vertebrate host blood-specific spirochete survival in Ixodes scapularis nymphs using artificial feeding chambers","volume":"9","author":"Hart","year":"2018","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2019.10.073_b0220","doi-asserted-by":"crossref","first-page":"e12998","DOI":"10.1111\/cmi.12998","article-title":"Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts","volume":"21","author":"Marcinkiewicz","year":"2019","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2019.10.073_b0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0167-4838(92)90424-C","article-title":"Structural analysis of an outer surface protein from the Lyme disease spirochete, Borrelia burgdorferi, using circular dichroism and fluorescence spectroscopy","volume":"1120","author":"France","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2019.10.073_b0230","doi-asserted-by":"crossref","first-page":"e0148497","DOI":"10.1371\/journal.pone.0148497","article-title":"The position of his-tag in recombinant OspC and application of various adjuvants affects the intensity and quality of specific antibody response after immunization of experimental mice","volume":"11","author":"Krupka","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.10.073_b0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/srep00005","article-title":"SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure","volume":"1","author":"Walker","year":"2011","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.10.073_b0240","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1073\/pnas.87.10.3768","article-title":"Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice","author":"Schaible","year":"1990","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.vaccine.2019.10.073_b0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0092-8674(80)90619-4","article-title":"Mechanism of action of cytochalasin B on actin","volume":"20","author":"MacLean-Fletcher","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.10.073_b0250","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20052471","article-title":"Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide","volume":"203","author":"Steere","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.10.073_b0255","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.0305680101","article-title":"An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope","volume":"101","author":"Willett","year":"2004","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:16Z","timestamp":1759401496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19314628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19314628"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}